FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

FGEN has been the topic of a number of other reports. HC Wainwright raised FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Trading Up 6.5 %

NASDAQ FGEN opened at $0.55 on Thursday. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.80. The stock has a market cap of $55.88 million, a P/E ratio of -0.45 and a beta of 0.75. The stock’s fifty day moving average price is $0.49 and its 200-day moving average price is $0.43.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the company posted ($0.52) earnings per share. As a group, analysts forecast that FibroGen will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 1,358,194 shares in the last quarter. FMR LLC increased its holdings in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares in the last quarter. Franklin Street Advisors Inc. NC boosted its position in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in FibroGen in the third quarter worth about $307,000. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.